this post was submitted on 09 May 2021
9 points (100.0% liked)
World News
32895 readers
522 users here now
News from around the world!
Rules:
-
Please only post links to actual news sources, no tabloid sites, etc
-
No NSFW content
-
No hate speech, bigotry, propaganda, etc
founded 5 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
It's not just about the production capacity of India. India currently has two vaccines - Covishield (Oxford & AstraZeneca developed, manufactured by Serum Institute of India) and Covaxin (Indian Council of Medical Research & Bharat BioTech, manufactured by Bharat BioTech). Sputnik V is a new addition from Russia.
While it would be wise to blame the country for the under production of Covaxin, because it's a home grown vaccine and public money was involved in its development. It could've been manufactured by more than one manufacturer in the country.
But, in case of Covishield, only SII has the license to manufacture it. If the IP rules are to be waived, it could be manufactured by others in the country.
The whole point is, countries like India have the capability to mass produce vaccines to satisfy domestic needs and to help other countries that don't have the necessary facilities to do so. The rich countries have secured enough vaccines (How rich countries are making the pandemic last longer) and in the case of UK, they have clause in the vaccine contracts to give it more preference, should the producer face shortages (link).